In a groundbreaking development poised to redefine neuromodulation therapies, researchers have harnessed the power of kilohertz-frequency electrical blocking to precisely mitigate unwelcome motor side effects during vagus nerve stimulation (VNS). This innovative approach, demonstrated in a swine model by Cheng, Deshmukh, Gholston, and colleagues, promises to address one of the most significant challenges in the clinical application of VNS—namely, its off-target motor activations that have long hindered therapeutic efficacy and patient comfort.
The vagus nerve, a critical component of the parasympathetic nervous system, innervates a myriad of organs and tissues, influencing heart rate, digestion, and inflammatory responses. VNS, which involves delivering electrical pulses to this nerve, has emerged as a transformative treatment for conditions ranging from epilepsy and depression to inflammatory diseases. Despite these successes, the stimulation often causes inadvertent activation of neighboring motor fibers, eliciting muscle contractions in the neck and throat, which can be both uncomfortable and clinically problematic.
Previous strategies to refine VNS have focused extensively on adjusting stimulation parameters or surgically refining electrode placement. However, these approaches frequently fall short of eliminating off-target effects, as the vagus nerve’s intricate anatomy encompasses a complex mixture of sensory, motor, and autonomic fibers tightly bundled within a single nerve sheath. This complexity calls for a more nuanced method to selectively inhibit undesired motor activation without compromising therapeutic benefits.
Cheng and colleagues’ research introduces the application of kilohertz-frequency alternating current (KHFAC) block as a solution to this intricate problem. Unlike conventional stimulation frequencies designed to activate nerve fibers, KHFAC employs ultrahigh-frequency electrical signals to induce reversible nerve conduction blockades. By delivering these kilohertz-frequency signals alongside or in alternation with therapeutic VNS pulses, the team demonstrated a significant reduction in motor fiber activation, effectively “silencing” the off-target pathways while preserving the desired autonomic modulation.
Their experimental design employed a sophisticated electrode array capable of both stimulating and blocking distinct subsets of the vagus nerve fibers in swine, a model chosen for its remarkable anatomical and physiological similarity to humans. Through meticulous electrophysiological recordings and behavioral assessments, the researchers quantified both nerve conduction and muscle responses, establishing a clear correlation between the application of KHFAC and the suppression of motor artifacts. Remarkably, the motor block achieved was immediate and reversible, underscoring the precision and safety of this technique.
One of the pivotal findings was the delineation of optimal kilohertz frequency ranges that maximized block efficacy while minimizing energy consumption and potential tissue heating—a critical consideration for implantable medical devices. The researchers noted that the frequency window between 5 and 20 kHz achieved these dual objectives, balancing block potency with biocompatibility. This insight likely expediates the translation of KHFAC-block VNS from experimental settings to clinical practice.
Moreover, the distinction between fiber types based on diameter and myelination was exploited to further refine the approach. The kilohertz block preferentially targets larger, fast-conducting motor fibers while sparing smaller, slower-conducting autonomic fibers, granting unprecedented fiber-selectivity in neuromodulation. This level of specificity opens new avenues to tailor therapies for individual patient needs, potentially reducing side effects in a manner previously unattainable.
The implications of these findings reverberate beyond VNS applications. Kilohertz-frequency blocking could serve as a universal tool to improve selectivity in various neuroprosthetic devices or bioelectronic medicines. By providing dynamic control over peripheral nerve conduction, devices can be programmed to maximize therapeutic benefits while minimizing adverse effects, thus fostering safer long-term implantation and patient compliance.
From a technology standpoint, incorporating KHFAC block into existing VNS hardware requires nuanced electromechanical integration. The research team’s electrode design balances miniaturization with multifunctionality, integrating stimulation and blocking electrodes within a singular cuff interface. This integrated approach simplifies surgical implantation and reduces foreign body burden, enhancing biostability and long-term function.
Cheng et al. also addressed potential safety concerns related to prolonged high-frequency stimulation. Chronic in vivo studies in swine demonstrated minimal nerve damage or inflammatory response, as evidenced by histological analyses post-experimentation. These promising safety profiles suggest long-term use of KHFAC block is viable, further cementing its clinical potential.
Beyond the technical parameters, the clinical translation pathway appears well-defined. Swine anatomy and physiology align closely with human vagus nerve characteristics, ensuring that scaling this technology for human trials will retain fidelity. The researchers have laid foundational work for preliminary human feasibility studies, indicating that the technology’s leap to bedside application is both imminent and achievable.
The therapeutic spectrum for VNS coupled with KHFAC block is extensive. Beyond seizure and mood disorder management, modulating inflammatory and metabolic pathways via vagus nerve presents exciting frontiers where precision control is crucial. For instance, selectively targeting autonomic fibers while blocking motor activation could enhance treatment tolerability in rheumatoid arthritis, heart failure, and even obesity.
This novel approach also addresses a critical bottleneck in patient adherence. The motor side effects associated with traditional VNS, such as throat tightness or voice hoarseness, often limit treatment continuation. By virtually eliminating these symptoms, KHFAC block can improve quality of life and treatment persistence, key determinants of clinical success.
Furthermore, the reversible nature of the kilohertz block opens the possibility of “on-demand” modulation, where motor fibers are only blocked transiently during therapeutic pulse delivery, preserving normal nerve function between sessions. This temporal control adds an additional layer of safety and adaptability, aligning with personalized medicine paradigms.
The study’s rigorous quantitative methodologies, leveraging electromyographic measurements and nerve conduction velocity analyses, set a new bar for research standards in neuromodulation. Their transparent reporting of dose-response relationships and parameter optimization paves the way for reproducibility and fixation of clinical guidelines.
Looking ahead, integration with closed-loop neuromodulation systems—where feedback from physiological sensors dynamically adjusts stimulation and blocking parameters—could revolutionize how chronic diseases are managed. By coupling sensory input with selective fiber block, devices could autonomously navigate the fine balance between efficacy and side-effect mitigation in real time.
In summation, the application of kilohertz-frequency block to reduce the off-target motor effects in VNS represents a transformative leap for bioelectronic medicine. It elegantly resolves long-standing anatomical and electrophysiological challenges, promising enhanced patient outcomes and expanded therapeutic indications. The synergy of advanced neuroengineering, rigorous clinical modeling, and forward-looking translational strategies encapsulates a new chapter in neural interfacing technologies.
As the medical community anticipates human trials, this pioneering research fuels hope for neurologic and systemic disorders that have long resisted effective, low-side-effect interventions. The capacity to selectively silence nerve fibers without permanent damage heralds a future where neuromodulation therapies can be deployed with unprecedented precision and safety. Such innovations exemplify how fundamental engineering principles can converge with biological complexity to alleviate human suffering in novel and profound ways.
Subject of Research: Selective nerve fiber blocking in vagus nerve stimulation to minimize off-target motor effects.
Article Title: Application of kilohertz-frequency block to mitigate off-target motor effects of vagus nerve stimulation in swine.
Article References:
Cheng, K.P., Deshmukh, A., Gholston, A.K. et al. Application of kilohertz-frequency block to mitigate off-target motor effects of vagus nerve stimulation in swine. Nat Commun (2025). https://doi.org/10.1038/s41467-025-67823-0
Image Credits: AI Generated
Tags: addressing muscle contractions in vagus stimulationchallenges in clinical application of VNSimproving therapeutic efficacy in VNSkilohertz-frequency electrical blockingminimizing discomfort in vagus nerve therapiesmotor side effects in VNSneuromodulation therapies advancementsoff-target effects in neuromodulationrefining VNS stimulation parametersswine model research in VNSvagus nerve and parasympathetic nervous systemvagus nerve stimulation innovations
